platoseedplatoseed
First personalized migraine clinic using genetics and telehealth.
Mable is a personalized migraine clinic using DNA to find and provide the right medication alongside continuous expert care Using our approach, patients have an 80% higher treatment satisfaction rate, have one extra day per week to enjoy their life and get 55% pain reduction.
Mable is a genomics-based telehealth platform focused on personalized migraine care. It combines genetic data and biomarkers with remote consultations to tailor treatment plans for migraine patients.
Mable operates an entirely virtual platform where patients start with an online consultation, undergo DNA testing to gather genetic and biomarker data, and receive precision medicine options. The platform analyzes genetic markers to inform individualized treatment plans and provides ongoing telehealth support to adjust treatments as needed based on patient progress and condition changes.
Who it’s for: Migraine patients seeking personalized, genomics-informed care delivered via telehealth
Funding round noted (seed funding of USD 3.2 million in 2022), founding team and telehealth/genomics focus
Roman is a neuroscientist who has conducted several years of research on memory encoding in the brain, neuropharmacology and drug target characterization. During his PhD at Oxford University he uncovered a new mechanism causing brain-wide synchronization which is necessary for correct retrieval of complex memories. He also has an MSc in Neuroscience (Oxford, UK) and MSc in Biology (Tubingen, Germany).
Formerly “Neurolytic Healthcare Ltd”, “DiveHealth” · why startups rename →
Software for pharmacies to move beyond dispensing
Patient Intelligence Platform for Genetic Disease
